Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013

Kudo, Masatoshi

doi:10.1159/000345882

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The electronic search identified 207 records after duplicates were removed, of which 29 full-text articles were assessed for eligibility [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. Of these, 4 were excluded because of different target conditions (i. e., lesions other than HCC or treatments other than RFA) [25,36,37,42], 2 evaluated LS by magnetic resonance elastography [18,21], and 14 for other reasons (▶ Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Of these, 4 were excluded because of different target conditions (i. e., lesions other than HCC or treatments other than RFA) [25,36,37,42], 2 evaluated LS by magnetic resonance elastography [18,21], and 14 for other reasons (▶ Fig. 1) [17,19,20,22,24,26,28,29,30,35,39,40,41,44]. Finally, a total of 9 studies [23,27,31,32,33,34,38,43,45] were included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Can Liver Ultrasound Elastography Predict the Risk of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation? A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Purpose The role of liver stiffness (LS) on ultrasound elastography in the prediction of hepatocellular carcinoma (HCC) recurrence after treatment with radiofrequency ablation (RFA) is still unclear. Our aim was to perform a systematic review and meta-analysis to assess whether LS can predict the recurrence of HCC after RFA. Materials and Methods Medline via PubMed, Embase, Scopus, and Cochrane Library databases, and abstracts of international conference proceedings were searched up to June 30, 2020. Cohort studies were included if they assessed the association between LS values measured by ultrasound elastography before RFA and HCC recurrence. Results 9 studies including 1373 patients with HCC treated by RFA, 643 of whom developed HCC recurrence, were identified. The mean value of LS before RFA was significantly higher in patients who developed HCC recurrence than in those who did not (weighted mean difference=11.98 kPa, 95%CI: 7.60–16.35, I2=63.8%). There was a significant positive association between LS value and HCC recurrence both at univariate (unadjusted HR=1.03, 95%CI: 1.00–1.07, I2=72.7%) and multivariate analysis (adjusted HR=1.03, 95%CI: 1.02–1.04, I2=0). Patients with LS value ≥13–14 kPa or >1.5 m/s have a higher risk of both HCC recurrence (unadjusted HR=2.18, 95%CI: 1.46–3.25, I2=49.7%; adjusted HR=2.41, 95%CI: 1.53–3.79, I2=0) and overall mortality (adjusted HR=4.38; 95%CI: 2.33–8.25, I2=0) in comparison with those with LS below these cutoffs. Conclusion Liver ultrasound elastography appears to be a reliable tool to predict HCC recurrence and overall survival after RFA. This technique may be useful for the management of patients with HCC treated by RFA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Can Liver Ultrasound Elastography Predict the Risk of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation? A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…28---30 These results have motivated some medical associations to incorporate the use of LS contrast agents in their diagnostic algorithms as evidence to be followed, once any abnormality is detected in the initial studies (ultrasound or high tumor marker level). 31,32 However, it should be taken into account that 5-12% of HCCs and close to 30% of high-grade dysplastic nodules are not hypointense in the LS contrast-enhanced hepatic phases, and there can even be a greater accumulation of contrast medium in the hepatobiliary phase. 14,16,24,30 This finding is possibly due to the paradoxical overexpression of the OATP8 genes and to the absence of functional bile ducts or the transporter outlet membrane in some tumors, in which case a different cellular origin or genetic alterations during hepatocarcinogenesis are contemplated.…”

Section: Evidence Of Gadoxetic Acid Usefulness In the Evaluation Of Fmentioning

confidence: 99%

Liver-specific gadoxetic acid-enhanced magnetic resonance for focal lesion evaluation

Cossio-Torrico

Ramírez-Carmona

Stoopen-Rometti

et al. 2015

Revista de Gastroenterología de México (English Edition)

View full text Add to dashboard Cite

Gadolinium-enhanced magnetic resonance for the evaluation of hepatic lesions is increasingly being used in clinical practice, especially in patients with suspicious focal lesions, whether benign or malignant. In regard to hepatocellular carcinoma, the diagnostic performance of magnetic resonance through the «conventional» protocols and multi-detector computerized tomography consisting of multiphase evaluation with intravenous contrast, largely depends on the size of the lesion. They are more reliable in lesions > 2 cm. However, in lesions measuring 1-2 cm, establishing the definitive diagnosis is a real challenge, with sensitivity values of 45-65%, but generally with excellent specificity (> 95%). Furthermore, if the lesion has a diameter < 1 cm, diagnosis is usually unreliable. In these last 2 settings, the complementary use of liver-specific contrast agents can be advantageous. The aim of our article was to review the current evidence on the usefulness of this new non-invasive diagnostic method in hepatic lesions.

show abstract

“…All the inflammatory, alcoholic, and autoimmune liver diseases can end in cirrhosis [44]. The etiology is different and with dynamic change in different areas in the world due to drug use, migration, and lifestyle change.…”

Section: Overview Of Liver Diseasesmentioning

confidence: 99%

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Guan

2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There is a vast body of knowledge which is ever-increasing about the treatment of liver disease with alternative and complementary medicine for which hundreds of thousands of literatures have been documented. Liver disease is a general term. This term covers all the potential problems that cause the liver to fail to perform its specified operations. Liver disease has a variety of presentations and causes a great public health problem worldwide which threatens the wellness of billions of people. Incidences of many types of liver disease are currently rising. Although there is still a debate about the entity of alternative and complementary medicine, it is now widely used and it is improving. And it covers the shortages and compensates for the weaknesses of conventional methods in the treatment of liver diseases. Alternative and complementary medicine for liver diseases provides benefits by regulating immunity, controlling disease progression, improving quality of life, and prolonging survival. This paper reviews the increasing interest and growing research into alternative and complementary medicine for liver diseases, with a look at the rough classification, principle of management, evidence-based applications, and issues for prescription and perspectives.

show abstract

Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013

Cited by 4 publications

References 24 publications

Can Liver Ultrasound Elastography Predict the Risk of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation? A Systematic Review and Meta-Analysis

Can Liver Ultrasound Elastography Predict the Risk of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation? A Systematic Review and Meta-Analysis

Liver-specific gadoxetic acid-enhanced magnetic resonance for focal lesion evaluation

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Contact Info

Product

Resources

About